


Product Data Sheet

MOG (35-55)

Cat. No.:	A8306
CAS No.:	149635-73-4
Formula:	C118H177N35O29S
M.Wt:	2581.97
Synonyms:	
Target:	Metabolism
Pathway:	Neuronal Metabolism
Storage:	Desiccate at -20°C



Solvent & Solubility

≥32.25 mg/mL in H₂O; insoluble in EtOH; ≥86 mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	Concentration			
	1 mM	0.3873 mL	1.9365 mL	3.8730 mL
	5 mM	0.0775 mL	0.3873 mL	0.7746 mL
	10 mM	0.0387 mL	0.1937 mL	0.3873 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Minor component of CNS myelin

IC₅₀ & Target

In Vitro

Cell Viability Assay

Cell Line: Brain endothelial cells

Preparation method: The solubility of this compound in sterile water is 0.50 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting conditions: 0 ~ 50 µg/mL; 48 hrs

	Applications:	MOG (35-55) significantly decreased the protein concentration in a dose-dependent manner. In cells treated with MOG (35-55) (50 µg/mL) + CFA + PTX, the protein concentration decreased to 37.6% of the level in the CON cells. At the doses of 25 or 50 µg/mL, MOG (35-55) emulsion substantially increased the activities of NADPH oxidase and MMP-9 (44.1 ~ 48.5% and 2-fold higher than those in the CON cells, respectively).
In Vivo	Animal experiment	
	Animal models:	C57BL/6 mice
	Dosage form:	50, 100 or 150 µg; s.c.
	Applications:	At the doses of 50 and 100 µg, MOG (35-55) induced more dramatic weight losses during the course of the MS-like disease, when compared with mice injected with 150 µg MOG (35-55). At day 17 after treatment, 3/5 mice in the 50 µg MOG (35-55) group were moribund whereas 4/5 mice still survived in the 100 and 150 µg dose groups. However, no clinical sign and disease progression were observed in these 3 groups of mice.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

1. Xu L, Zhang C, et al. "Rapamycin combined with MCC950 to treat multiple sclerosis in experimental autoimmune encephalomyelitis." J Cell Biochem. 2018 Oct 15. PMID:30320900

See more customer validations on www.apexbt.com.

References

- [1]. Seo JE, Hasan M, Rahaman KA, Kang MJ, Jung BH, Kwon OS. A leading role for NADPH oxidase in an in-vitro study of experimental autoimmune encephalomyelitis. Mol Immunol. 2016 Apr;72:19-27.
- [2]. Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt

of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

